Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & 3rd Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

 

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

William Nathaniel Brennen, Ph.D.

Headshot of William Nathaniel Brennen
  • Assistant Professor of Oncology

Research Interests

Cell-based therapeutics and the tumor microenvironment. ...read more

Background

Titles

  • Assistant Professor of Oncology
  • Assistant Professor of Urology

Departments / Divisions

Education

Degrees

  • Ph.D.; Johns Hopkins University School of Medicine (Maryland) (2011)
  • B.A.; University of Delaware (Delaware) (2002)

Research & Publications

Selected Publications

Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, Isaacs JT, Karp JM. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials. 2016 Jun; 91: 140-50. PMID: 27019026. 

Brennen WN, Rosen DM, John T. Isaacs, Denmeade SR. Targeting carcinoma associated fibroblasts within the reactive stroma with a fibroblast activation protein (FAP)-activated prodrug. JNCI. 2012, Sept 5; 104(17): 1320-34. PMID: 22911669.

Brennen WN, Chen S, Denmeade SR, Isaacs JT. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget. 2013 Jan; 4(1): 106-17. PMID: 23362217.

Brennen WN, Drake CG, Isaacs JT. Enhancement of the T-cell Armamentarium as a Cell-based Therapy for Prostate Cancer. Cancer Res. 2014 Jul 1; 74(13): 3390-5. PMID: 24747912.

Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer. 2013 Aug 23; 20(5): R269-90. PMID: 23975882.

Is this you? Edit Profile
back to top button